The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khadhouri Sinan, Gallagher Kevin M, MacKenzie Kenneth R, Shah Taimur T, Gao Chuanyu, Moore Sacha, Zimmermann Eleanor F, Edison Eric, Jefferies Matthew, Nambiar Arjun, Mannas Miles P, Lee Taeweon, Marra Giancarlo, Lillaz Beatrice, Gómez Rivas Juan, Olivier Jonathan, Assmus Mark A, Uçar Taha, Claps Francesco, Boltri Matteo, Burnhope Tara, Nkwam Nkwam, Tanasescu George, Boxall Nicholas E, Downey Alison P, Lal Asim A, Antón-Juanilla Marta, Clarke Holly, Lau David H W, Gillams Kathryn, Crockett Matthew, Nielsen Matthew, Takwoingi Yemisi, Chuchu Naomi, O'Rourke John, MacLennan Graeme, McGrath John S, Kasivisvanathan Veeru, IDENTIFY Study group
Аннотация
PATIENTS AND METHODS: This was an international multicentre prospective observational study. We included patients aged ≥16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries.
RESULTS: Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05; P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15; P < 0.001), male sex 1.30 (95% CI 1.14-1.50; P < 0.001), and smoking 2.70 (95% CI 2.30-3.18; P < 0.001).
CONCLUSIONS: A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer.